Axsome Therapeutics (AXSM) PT Set at $10.00 by HC Wainwright

Share on StockTwits

HC Wainwright set a $10.00 price objective on Axsome Therapeutics (NASDAQ:AXSM) in a report issued on Tuesday morning. The brokerage currently has a buy rating on the stock.

Separately, Zacks Investment Research raised shares of Axsome Therapeutics from a sell rating to a hold rating in a research report on Thursday, September 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of Hold and an average price target of $11.38.

AXSM stock opened at $3.16 on Tuesday. Axsome Therapeutics has a twelve month low of $2.05 and a twelve month high of $5.95. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.26 and a quick ratio of 2.26. The company has a market cap of $90.57 million, a PE ratio of -2.65 and a beta of -0.15.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Wednesday, August 8th. The company reported ($0.32) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.32). On average, analysts anticipate that Axsome Therapeutics will post -1.15 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in the business. Alethea Capital Management LLC boosted its holdings in Axsome Therapeutics by 132.5% in the second quarter. Alethea Capital Management LLC now owns 270,823 shares of the company’s stock worth $867,000 after purchasing an additional 154,323 shares during the period. Sio Capital Management LLC acquired a new position in Axsome Therapeutics in the first quarter worth $474,000. Finally, A.R.T. Advisors LLC acquired a new position in Axsome Therapeutics in the first quarter worth $145,000. 15.63% of the stock is owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.

See Also: Understanding each part of a balance sheet

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply